Search clinical trials for: Fludarabine, Cyclophosphamide

Total 4219 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
Case Comprehensive Cancer Center

Completed

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia | SCD

United States
Genzyme, a Sanofi Company

Completed

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Leukemia, Lymphocytic, Chronic, B-Cell
University of Rochester

Completed

URMC Related Haplo-identical Donor BMT (HaploOnly)

Lymphoma | Multiple Myeloma | Myelofibrosis | Solid Tumors | Hematological Disease | Immune Deficiencies

United States
Shanghai Jiao Tong University School of Medicine

Recruiting

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
M.D. Anderson Cancer Center

Terminated

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Leukemia | Pediatric Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage III Small Lymphocytic Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma | Stage IV Small Lymphocytic...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Children's Hospital of Philadelphia

Recruiting

Fludarabine Based RIC for Bone Marrow Failure Syndromes

Bone Marrow Failure Syndromes

United States
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis

Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class III

United States
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Recruiting

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

T-cell Lymphoma | T-cell Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Imugene Limited

Recruiting

Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Non-Hodgkin Lymphoma | B-cell Acute Lymphoblastic Leukemia

United States
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Fujian Cancer Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Unknown

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma

China
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Australia, Brazil, Spain, Italy, Canada, Germany, Chile, Mexico, France, Argentina, Croatia, Russian Federation, Slovakia, Turkey, Poland, Czechia, New Zealand, Portugal, Greece
Hoffmann-La Roche

Completed

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Israel
Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Unknown

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

China
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Shanghai 6th People's Hospital
Hrain Biotechnology Co., Ltd.

Recruiting

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Ovarian Cancer

China
Fate Therapeutics

Terminated

FT538 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myeloma | AML, Adult

United States
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Mesothelin-positive Advanced Refractory Solid Tumors

China
Kite, A Gilead Company

Approved for marketing

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)

Relapse/Refractory Mantle Cell Lymphoma

United States
Hoffmann-La Roche

Completed

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Spain
National Cancer Institute (NCI)

Terminated

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
University of Pittsburgh
Genentech, Inc.; Biogen

Completed

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Istituto Clinico Humanitas

Unknown

Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas

Lymphoma

Italy
Samsung Medical Center

Unknown

Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

Lymphoma | AML | MDS | CML | ALL

Korea, Republic of
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

China
University of Pennsylvania

Recruiting

GFRα4 CAR T Cells in MTC Patients

Metastatic Medullary Thyroid Cancer

United States
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Active, not recruiting

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

POMES Syndrome | Relapsed and Refractory POMES Syndrome

China
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Second Affiliated... and other collaborators

Unknown

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

CD19-positive ALL

China
Peking University People's Hospital

Unknown

Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA

Aplastic Anemia | Stem Cell Transplant Complications | Engraft Failure

China
Milton S. Hershey Medical Center

Terminated

A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Skin Cancer | Metastatic Melanoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Lymphoproliferative Disorders | Leukemia | Multiple Myeloma | Myelodysplastic Disorders | Plasma Cell Dyscrasia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome

United States
Peking University People's Hospital

Recruiting

ATG Plus Low-dose PT-Cy for GVHD Prevention

Hematologic Malignancy

China
Priv.-Doz. Dr. med. Joachim Rom

Completed

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Epithelial Ovarian Cancer

Germany
National Cancer Institute (NCI)

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental | Experimental Melanomas

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Suspended

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell Transplantation | Immunodeficiency

United States

Search clinical trials for: Fludarabine, Cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations